234 related articles for article (PubMed ID: 11497348)
1. Topical and transdermal delivery of antisense oligonucleotides.
Brand RM
Curr Opin Mol Ther; 2001 Jun; 3(3):244-8. PubMed ID: 11497348
[TBL] [Abstract][Full Text] [Related]
2. Parameters controlling topical delivery of oligonucleotides by electroporation.
Regnier V; Le Doan T; Préat V
J Drug Target; 1998; 5(4):275-89. PubMed ID: 9713977
[TBL] [Abstract][Full Text] [Related]
3. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
Pannier AK; Arora V; Iversen PL; Brand RM
Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture.
Bennett CF; Mirejovsky D; Crooke RM; Tsai YJ; Felgner J; Sridhar CN; Wheeler CJ; Felgner PL
J Drug Target; 1998; 5(3):149-62. PubMed ID: 9606005
[TBL] [Abstract][Full Text] [Related]
5. Topical delivery of active principles: the field of dermatological research.
Nino M; Calabrò G; Santoianni P
Dermatol Online J; 2010 Jan; 16(1):4. PubMed ID: 20137746
[TBL] [Abstract][Full Text] [Related]
6. Liposomal systems as drug delivery vehicles for dermal and transdermal applications.
Pierre MB; Dos Santos Miranda Costa I
Arch Dermatol Res; 2011 Nov; 303(9):607-21. PubMed ID: 21805180
[TBL] [Abstract][Full Text] [Related]
7. Visualization of skin penetration using confocal laser scanning microscopy.
Alvarez-Román R; Naik A; Kalia YN; Fessi H; Guy RH
Eur J Pharm Biopharm; 2004 Sep; 58(2):301-16. PubMed ID: 15296957
[TBL] [Abstract][Full Text] [Related]
8. Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles.
Ita K
Biomed Pharmacother; 2017 Mar; 87():311-320. PubMed ID: 28064104
[TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of antisense oligonucleotides.
Brand RM; Iversen PL
Methods Mol Med; 2005; 106():255-69. PubMed ID: 15375321
[No Abstract] [Full Text] [Related]
10. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
11. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis.
Kim ST; Lee KM; Park HJ; Jin SE; Ahn WS; Kim CK
J Gene Med; 2009 Jan; 11(1):26-37. PubMed ID: 19006098
[TBL] [Abstract][Full Text] [Related]
12. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery.
Wang Y; Thakur R; Fan Q; Michniak B
Eur J Pharm Biopharm; 2005 Jul; 60(2):179-91. PubMed ID: 15939232
[TBL] [Abstract][Full Text] [Related]
13. Transdermal delivery of antisense compounds.
Brand RM; Iversen PL
Adv Drug Deliv Rev; 2000 Oct; 44(1):51-7. PubMed ID: 11035197
[TBL] [Abstract][Full Text] [Related]
14. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
15. Transdermal drug delivery systems: skin perturbation devices.
Brown MB; Traynor MJ; Martin GP; Akomeah FK
Methods Mol Biol; 2008; 437():119-39. PubMed ID: 18369965
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
Mirabelli CK; Bennett CF; Anderson K; Crooke ST
Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
[TBL] [Abstract][Full Text] [Related]
17. [Current status of antisense drugs].
Li XJ
Sheng Li Ke Xue Jin Zhan; 2000 Apr; 31(2):115-9. PubMed ID: 12545727
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
19. Iontophoretic drug delivery.
Kalia YN; Naik A; Garrison J; Guy RH
Adv Drug Deliv Rev; 2004 Mar; 56(5):619-58. PubMed ID: 15019750
[TBL] [Abstract][Full Text] [Related]
20. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides.
Roy S; Zhang K; Roth T; Vinogradov S; Kao RS; Kabanov A
Nat Biotechnol; 1999 May; 17(5):476-9. PubMed ID: 10331808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
